SCHEMBL4172925

SCHEMBL4172925

Cc1nccc(C2CCCN2C(=O)c2csc(NS(=O)(=O)c3ccccc3)n2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC3 Q13507 4/20 0.49
TRPC6 Q9Y210 4/20 0.49
SCN9A Q15858 6/20 0.47
TRPV1 Q8NER1 2/20 0.42
TRPA1 O75762 1/20 0.42
CACNA1C Q13936 1/20 0.42
SCN5A Q14524 1/20 0.42
TRPV4 Q9HBA0 1/20 0.42
ALDH1A1 P00352 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SCD5 Q86SK9 1/20 0.39
PKM P14618 1/20 0.38
KDM1A O60341 1/20 0.38
SCD O00767 1/20 0.37
USP2 O75604 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180201 0.88 SCN9A (0.49) TRPC3TRPC6SCN9ATRPV1TRPA1
SCHEMBL4177283 0.85 TRPC3 (0.51) TRPC3TRPC6SCN9AALDH1A1SCD5
SCHEMBL4172975 0.85 TRPC3 (0.51) TRPC3TRPC6SCN9AALDH1A1SCD5
SCHEMBL4172599 0.84 TRPC3 (0.61) TRPC3TRPC6SCN9ATRPV1TRPA1
SCHEMBL4169816 0.84 TRPC3 (0.51) TRPC3TRPC6SCN9AALDH1A1SCD5
SCHEMBL4176159 0.82 TRPC3 (0.61) TRPC3TRPC6SCN9ATRPV1TRPA1
SCHEMBL4165105 0.82 TRPC3 (0.66) TRPC3TRPC6SCN9AALDH1A1CYP2C9
SCHEMBL4181512 0.81 TRPC3 (0.71) TRPC3TRPC6SCN9ATRPV1TRPA1
SCHEMBL4177448 0.81 TRPC3 (0.54) TRPC3TRPC6SCN9ATRPV1TRPA1
SCHEMBL4170692 0.81 TRPC3 (0.65) TRPC3TRPC6SCN9AALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 TRPC3 57/4885TRPC6 84/4885SCN9A 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.